Doylestown, Pennsylvania-based Aprea Therapeutics, Inc. is making strides in its mission to create and distribute cancer therapeutics that utilize synthetic lethality. The biopharmaceutical company is concentrating its efforts on attacking a critical DNA damage response pathway and central targets in cancer progression. ATRN-119, the firm's premier program, is a small molecule ATR inhibitor that is currently undergoing clinical testing for the treatment of solid tumors.